FDA Approves New Non-Opioid Pain Medication

Translate to Spanish or other 102 languages!

Every year, thousands of people die from overdosing on opioids in the United States. But a new non-opioid pain medication, which was just approved by the FDA, could help change that. Image for illustration purposes
Every year, thousands of people die from overdosing on opioids in the United States. But a new non-opioid pain medication, which was just approved by the FDA, could help change that. Image for illustration purposes
- Advertisement -

Every year, thousands of people die from overdosing on opioids in the United States. But a new non-opioid pain medication, which was just approved by the FDA, could help change that. 

“80 million people suffer from acute pain, whether from surgery, trauma or other injuries,” said Jianguo Cheng, MD, PhD, anesthesiologist for Cleveland Clinic. “The current mainstream treatment is opioids. You can use NSAIDS and other medications, but usually it’s not as effective. So therefore, this really is a new class of drug.”

Dr. Cheng was not involved with researching Suzetrigine, but said the drug could be helpful, especially since it is considered non-addictive.

- Advertisement -

He explains that it works by targeting a pain-signaling pathway in the peripheral nervous system – similar to how an anti-depressant or anti-seizure medication does in the central nervous system.

So, who would be prescribed this drug?

Dr. Cheng said it would typically be given to someone after surgery or trauma.

He notes, however, this wouldn’t stop the use of opioids altogether but could instead be an alternative when appropriate.

- Advertisement -

“Maybe not as good as a strong opioid, but it does bridge the gap between no opioid, a weak opioid and strong opioid,” he said. “This is something in-between that can be applicable for a large number of patients.”

Some of the drugs most common side effects include itching, muscle spasms, and rash. 

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk 

The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” 

Practical Health Tips to Navigate Cold and Flu Season Safely

With cold and flu season in full swing, experts say there are some simple steps you can take to protect yourself and those around you.

New Therapy for Head and Neck Squamous Cell Carcinoma Receives Accelerated FDA Approval

The U.S. Food and Drug Administration today granted accelerated approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for the treatment of adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after platinum-based chemotherapy and immunotherapy.

DHR Health to Host 13th Annual Circle of Care Caregivers Conference

DHR Health Rehabilitation Hospital will host its 13th Annual Circle of Care Caregivers Conference on Saturday, November 7, 2026, at the Edinburg Conference Center at Renaissance, offering educational presentations and resources for individuals caring for family members and loved ones.
- Advertisement -